Answers are grounded in this paper and cite their sources.
The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.
No takes yet. Share an insight, caveat, or question.
Younes et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: